Skip to content
Makers Laboratories logo

Makers Laboratories

MAKERSL NSE
₹215.10 +13.19 (+6.53%)
P/E
37.21
View as Markdown
MCP
Close 4 Nov 2026 ₹215.10 +85.75 +66.3% 1Y
Start ₹129.35

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
9.28%
Debt to Equity
0.12
EPS (TTM)
₹5.78
Book Value
₹123.59
Market Cap
—
P/E (TTM)
37.21
P/B
1.74
ROE
3.17%
Dividend Yield
0.00%
EBITDA
₹16.40 Cr
52W High
₹236.00
52W Low
₹109.00
Day Range
₹200.33 – ₹232.00
Volume
63,556

Peer Comparison

Healthcare › Pharmaceuticals

Makers Laboratories peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Makers Laboratories (this company)
₹215.1037.21₹121 Cr1.740.00%3.17%9.28%₹148 Cr₹11 Cr
Median 8 companies₹1,587.7038.01₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

58 Good

Data confidence 100/100

Category scores

Quality
56
Good
Returns, margins, earnings quality 22% weight
Valuation
52
Average
Cheap vs sector & own history 24% weight
Growth
63
Good
Sales & profit trajectory 9% weight
Financial Health
59
Good
Solvency, leverage, coverage 9% weight
Momentum
95
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 49.3% CAGR over last 5 years
  • Debtor days have improved from 68.8 to 51.6 days.

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of -2.05% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1513
OscillatorsBullish153
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
63.83
Neutral
MACD (12,26,9)
5.24
Bullish
SMA (50)
191.35
Bullish
SMA (200)
159.21
Bullish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+15.36%
3Y+11.76%
1Y+16.53%
TTM+17.60%

Net profit

Net profit growth by window
5Y+51.57%
3YTurned to profit
1Y−27.27%
TTM−13.49%

Operating cash flow

Operating cash flow growth by window
5YZero base
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−0.95 pp
3Y+7.67 pp
1Y+3.20 pp
TTM+4.98 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2021₹69.00 Cr
Mar 2022₹127 Cr
Mar 2023₹101 Cr
Mar 2024₹104 Cr
Mar 2025₹121 Cr
Mar 2026₹141 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2021₹1.00 Cr
Mar 2022₹12.00 Cr
Mar 2023−₹2.00 Cr
Mar 2024−₹5.00 Cr
Mar 2025₹11.00 Cr
Mar 2026₹8.00 Cr

Quarterly Results

₹ Cr
506919 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
25.01
25.06
26.51
27.81
29.59
29.57
27.69
33.9
35
34.17
35.67
35.75
42.77
Expenses
25.15
24.86
26.31
26.95
27.78
27.38
26.38
30.81
31.99
31.89
31.51
30.47
35.81
Operating Profit
−0.14
0.2
0.2
0.86
1.81
2.19
1.31
3.09
3.01
2.28
4.16
5.28
6.96
OPM %
−0.56%
0.8%
0.75%
3.09%
6.12%
7.41%
4.73%
9.12%
8.6%
6.67%
11.66%
14.77%
16.27%
Other Income
0.25
0.41
0.37
0.43
−0.51
10.63
0.87
0.1
0.27
0.36
0.33
0.76
0.61
Interest
0.41
0.49
0.53
0.52
0.49
0.43
0.19
0.18
0.18
0.22
0.2
0.17
0.15
Depreciation
1.11
1.13
1.16
1.15
1.28
1.29
1.31
0.9
1.12
1.13
1.14
1.13
1.13
PBT
−1.41
−1.01
−1.12
−0.38
−0.47
11.1
0.68
2.11
1.98
1.29
3.15
4.74
6.29
Tax %
18.44%
10.89%
−4.46%
152.63%
48.94%
11.98%
60.29%
24.64%
34.85%
42.64%
27.94%
24.89%
27.03%
Net Profit
−1.66
−1.13
−1.06
−0.97
−0.7
9.76
0.27
1.58
1.29
0.74
2.27
3.56
4.59
EPS (₹)
−3.56
−2.27
−2.61
−2.19
−1.66
14.95
−0.51
−0.08
0.75
−0.2
1.59
1.85
2.54

Profit & Loss

₹ Cr
506919 profit and loss, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
69
127
101
104
121
141
148
Expenses
60
108
98
103
112
126
130
Operating Profit
8
19
3
1
9
15
19
OPM %
12%
15%
3.3%
1.1%
7%
11%
13%
Other Income
1
3
2
2
11
2
2
Interest
2
2
2
2
1
1
1
Depreciation
5
4
4
5
5
5
5
PBT
3
16
−1
−4
13
11
15
Tax %
50%
25%
161%
23%
19%
30%
—
Net Profit
1
12
−2
−5
11
8
11
EPS (₹)
−0.56
8.44
−8.05
−10.61
12.69
3.98
5.78
Div. Payout %
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
506919 balance sheet, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
6
6
6
6
Reserves
49
55
63
57
65
67
Borrowings
21
23
17
22
8
9
Other Liabilities
62
62
66
76
70
85
Total Liabilities
136
144
152
161
148
167
Fixed Assets
71
68
85
87
74
71
CWIP
0
9
0
0
1
4
Investments
2
0
0
3
0
12
Other Assets
63
66
67
71
73
81
Total Assets
136
144
152
161
148
167

Cash Flow

₹ Cr
506919 cash flow, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
18
−9
1
−4
14
Investing
0
−22
1
−7
20
−15
Financing
0
0
6
6
−16
0
Net Cash Flow
0
−3
−2
0
0
0
Free Cash Flow
0
9
−21
−6
11
11
CFO/EBITDA
0
128
−185
232
−20
118

Ratios

506919 financial ratios, annual
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
39
72
70
85
52
Inventory Days
344
166
281
227
230
250
Days Payable
182
38
91
112
79
110
Cash Conversion Cycle
250
167
262
185
236
192
Working Capital Days
112
61
113
97
140
106
ROCE %
—
15%
1%
−2%
4%
9%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Makers Laboratories insights

67 extracted metrics across FY08–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 61.27%
  • Public 31.47%
  • Others 6.87%
  • DIIs 0.39%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Makers Laboratories

What does Makers Laboratories Ltd do?
Incorporated in 1984, Makers Laboratories Ltd manufactures and markets around 200 pharma formulations.
Where is Makers Laboratories Ltd (MAKERSL) listed?
Makers Laboratories Ltd trades as MAKERSL on the NSE and under code 506919 on the BSE.
Which sector does Makers Laboratories Ltd belong to?
Makers Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Makers Laboratories Ltd?
Makers Laboratories Ltd trades at a PE ratio of 37.21 as of 4 Nov 2026, on earnings per share of ₹5.78, against a book value of ₹123.59 per share.
What is the 52-week high and low of Makers Laboratories Ltd?
Over the last 52 weeks Makers Laboratories Ltd has traded between ₹109 and ₹236 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Makers Laboratories Ltd?
Makers Laboratories Ltd reported a return on equity of 3.17%. Its debt-to-equity ratio is 0.12.

Company Information

Incorporated in 1984, Makers Laboratories Ltd manufactures and markets around 200 pharma formulations.

Website makerslabs.com
Listed 17 Aug 2026
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506919.md for Makers Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month